N-Hydroxymexiletine glucuronide | 151636-18-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-Hydroxymexiletine glucuronide
• 英文别名: (2S,3S,4S,5R,6S)-6-[[(2R)-1-(2,6-dimethylphenoxy)propan-2-yl]amino]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
• CAS: 151636-18-9
• 化学式: C₁₇H₂₅NO₈
• 分子量: 371.4
• InChiKey: XXMULGPNDWROEN-FHVJEIPNSA-N

物化性质

• 沸点：
  594.4±60.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  138
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• Therapeutic approaches for treating Parkinson's disease
  申请人：PHARNEXT

  公开号：US10010515B2

  公开（公告）日：2018-07-03

  The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.

  本发明涉及治疗帕金森病及相关疾病的组合物和方法。更具体地说，本发明涉及针对α-突触核蛋白聚集网络的帕金森病及相关疾病的新型组合疗法。特别是，本发明涉及可单独或以组合形式有效保护神经元细胞免受α-突触核蛋白聚集的化合物。本发明还涉及生产治疗帕金森病的药物或药物组合的方法，以及治疗帕金森病或相关疾病的方法。
• Nootropic compositions for improving memory performance
  申请人：PHARNEXT

  公开号：US10265304B2

  公开（公告）日：2019-04-23

  The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising at least two drugs selected from cinacalcet, baclofen, acamprosate, mexiletine, sulfisoxazole and torasemide useful to enhance memory and related functions in healthy subjects or subjects suffering from conditions or disorders having a negative impact on their memory.

  本发明涉及改善记忆和相关功能（如警觉性、注意力、集中力、学习和语言处理）的组合物和方法。更具体地说，本发明涉及由至少两种药物组成的组合物，这两种药物选自西那卡塞、巴氯芬、阿坎普罗斯酸、美西利汀、磺胺异噁唑和托拉塞米，这些药物有助于增强健康受试者或患有对其记忆力有负面影响的病症或紊乱的受试者的记忆力和相关功能。
• Compositions for treating amyotrophic lateral sclerosis
  申请人：PHARNEXT

  公开号：US10342784B2

  公开（公告）日：2019-07-09

  The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.

  本发明涉及治疗肌萎缩侧索硬化症的组合物和方法。 更具体地说，本发明涉及治疗肌萎缩性脊髓侧索硬化症或相关疾病的新型组合疗法。
• Compositions for treating neurological disorders
  申请人：PHARNEXT

  公开号：US10434109B2

  公开（公告）日：2019-10-08

  The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.

  本发明涉及治疗与谷氨酸兴奋毒性和淀粉样蛋白β毒性相关的神经系统疾病的组合物和方法。更具体地说，本发明涉及多发性硬化症、阿尔茨海默病、阿尔茨海默病相关疾病、肌萎缩侧索硬化症、帕金森病、亨廷顿病、神经性疼痛、酒精性神经病、酗酒或戒酒或脊髓损伤的新型组合疗法。
• NEW COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS
  申请人：Pharnext

  公开号：EP2680836B1

  公开（公告）日：2018-06-13